Premium
Cimetidine interaction with imipramine and nortriptyline
Author(s) -
Henauer Stephan A,
Hollister Leo E
Publication year - 1984
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1984.24
Subject(s) - nortriptyline , bioavailability , pharmacology , metabolite , tricyclic , desipramine , cimetidine , imipramine , chemistry , active metabolite , pharmacokinetics , drug interaction , amitriptyline , medicine , antidepressant , biochemistry , alternative medicine , pathology , hippocampus
The interaction between Cimetidine and two tricyclic antidepressants was examined in healthy subjects. One tricyclic, imipramine, is primarily metabolized to a demethylated active metabolite, desipramine. The other, nortriptyline, is largely metabolized to a 10‐hydroxylated metabolite. It was assumed that pretreatment with Cimetidine, because of its inhibition of metabolic pathways of both demethylation and hydroxylation as well as its ability to reduce hepatic extraction of these drugs, would increase bioavailability and decrease clearance of both drugs. Such was the case with imipramine, but the bioavailability of nortriptyline was not increased. Further, the bioavailability of the 10‐hydroxy metabolite of nortriptyline was increased rather than decreased. The degree of change in these kinetic variables varied widely between individuals. Thus it is not possible to predict which subjects might develop evidence of toxicity to tricyclics when Cimetidine is added to the treatment program. The monitoring of tricyclic plasma concentrations is probably desirable in such circumstances. Clinical Pharmacology and Therapeutics (1984) 35, 183–187; doi: 10.1038/clpt.1984.24